metaPreg - Centrally acting antiadrenergic (versus unexposed) during pregnancy

Centrally acting antiadrenergic (versus unexposed) updated on 03-11-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.41 [0.80, 2.50]	0%	3 studies	4,256	356	not evaluable	ROB	-
Major congenital malformations	1.41 [0.80, 2.50]	0%	3 studies	4,256	356	not evaluable	ROB	-
Congenital heart defects	1.12 [0.72, 1.72]	0%	2 studies	873	151	not evaluable	ROB	-
Digestive system anomalies	4.66 [1.54, 14.08]	-	1 study	362	55	not evaluable	ROB	8.79 [2.46; .]
Encephalocele	4.10 [1.50, 11.20]	-	1 study	206		not evaluable	ROB	7.67 [2.37; .]
Genital anomalies	5.37 [1.78, 16.21]	-	1 study	314	55	not evaluable	ROB	10.21 [2.96; .]
19 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	1.39 [0.95, 2.03]	73%	9 studies	11,003	2,971	not evaluable	ROB	-
Preterm (< 37 weeks)	2.35 [1.86, 2.97]	86%	6 studies	9,866	4,065	not evaluable	ROB	4.13 [3.12; .]
Low birth weight (< 2500g)	2.31 [1.45, 3.66]	91%	4 studies	11,011	1,700	not evaluable	ROB	4.04 [2.26; .]
Very preterm (28 to 32 weeks)	2.26 [1.77, 2.88]	-	1 study	303	1,760	not evaluable	ROB	3.94 [2.93; .]
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preeclampsia	2.46 [0.57, 10.50]	98%	4 studies	2,348	2,359	not evaluable	ROB	-
Caesarean	2.11 [2.03, 2.20]	0%	2 studies	31	4,029	not evaluable	ROB	3.64 [3.47; .]
Gestational diabetes	2.23 [1.36, 3.63]	-	1 study	76	191	not evaluable	ROB	3.88 [2.07; .]
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Low Apgar score (< 7) (at 5 min)	1.27 [0.35, 4.60]	56%	3 studies	1,046	477	not evaluable	ROB	-
Neonatal bradycardia	1.55 [0.55, 4.36]	53%	2 studies	54	248	not evaluable	ROB	-
Neonatal disorders (as a whole)	1.61 [0.97, 2.70]	0%	2 studies	73	224	not evaluable	ROB	-
Low Apgar score (< 7) (at 1 min)	1.95 [1.40, 2.71]	-	1 study	5,833	340	not evaluable	ROB	3.31 [2.16; .]
Low Apgar score (< 7) (NOS)	1.36 [1.29, 1.44]	-	1 study		1,382	not evaluable	ROB	2.06 [1.90; .]
6 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Late intrauterine deaths (> 22 weeks) / Stillbirths	0.97 [0.58, 1.62]	0%	4 studies	90	2,324	not evaluable	ROB	-
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	0.74 [0.16, 3.55]	48%	4 studies	60	435	not evaluable	ROB	-
Perinatal death	1.79 [0.95, 3.37]	0%	4 studies	1,392	430	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Cognitive developmental disorders/delay (3-6 years old)	2.75 [1.10, 6.87]	-	1 study		25	not evaluable	ROB	4.94 [1.43; .]
2 non statistically significant endpoints reported in only one study